16 suspended. 16 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Suspended 16 |
| Phase 1 | 6 | Suspended 6 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations Eltrombopag (EPAG) - Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | Phase 2 | Suspended | Abhay Singh, MD MPH | 25 | 2025-06-17 | 2026-10-09 |
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE Dasatinib - Acute Myeloid Leukemia | Phase 2 | Suspended | Institut Paoli-Calmettes | 35 | 2024-05-22 | 2026-10-01 |
| A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) fadraciclib - Leukemia, Myelodysplastic Syndrome(MDS) | Phase 1 / Phase 2 | Suspended | Cyclacel Pharmaceuticals, Inc. | 210 | 2021-10-22 | 2024-02-08 |
| Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia IBI188, Azacitidine, Decitabine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Suspended | Innovent Biologics (Suzhou) Co. Ltd. | 222 | 2020-09-25 | 2023-10-23 |
| Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Emavusertib, Venetoclax - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Suspended | Curis, Inc. | 366 | 2020-07-06 | 2026-03-19 |
| Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients Oshadi D & Oshadi R;, salvage therapy cytosar and mitoxantrone - Acute Myeloid Leukemia, Lymphoid Leukemia | Phase 2 | Suspended | Oshadi Drug Administration | 15 | 2017-01-01 | 2018-04-18 |
| CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation CLAM+PBSC - Leukemia | Phase 1 / Phase 2 | Suspended | Shanghai Jiao Tong University School of Medicine | 20 | 2016-09-01 | 2021-11-26 |
| Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients AS101 - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Suspended | BioMAS Ltd | 12 | 2015-01-01 | 2015-02-10 |
| Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia Alemtuzumab - B-cell Chronic Lymphocytic Leukemia | Phase 2 | Suspended | Shanghai Zhangjiang Biotechnology Limited Company | 120 | 2011-07-01 | 2022-06-21 |
| Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) KB004, Monoclonal Antibody - Myelodysplastic Syndrome (MDS), Myelofibrosis (MF) | Phase 1 / Phase 2 | Suspended | Humanigen, Inc. | 120 | 2010-09-01 | 2015-11-17 |
| L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes L-Ascorbic Acid - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Suspended | Samsung Medical Center | 25 | 1998-05-01 | 2006-10-26 |
| Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) Imatinib Mesylate - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) | Phase 2 | Suspended | Renato Melaragno | 20 | 2013-03-26 |
Leukemia, Myeloid, Acute (8) · Myelodysplastic Syndromes (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, Myelomonocytic, Chronic (2) · Lymphoma (2) · Neoplasms (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Burkitt Lymphoma (1) · Epstein-Barr Virus Infections (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
Hematologic Diseases (16) · Hemic and Lymphatic Diseases (16) · Neoplasms by Histologic Type (16) · Neoplasms (14) · Leukemia, Myeloid (9) · Bone Marrow Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Leukemia, Lymphoid (6) · Disease Attributes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5)
Cyclophosphamide (2) · Abatacept (1) · Alemtuzumab (1) · Antineoplastic Agents (1) · Ascorbic Acid (1) · Asparaginase (1) · Azacitidine (1) · CA-4948 (1) · CT-P10 (1) · CYC065 (1) · Dasatinib (1) · Decitabine (1) · Doxorubicin (1) · Etoposide (1) · Filgrastim (1)
Abhay Singh, MD MPH (1) · Armaceutica, Inc. (1) · BioMAS Ltd (1) · Curis, Inc. (1) · Cyclacel Pharmaceuticals, Inc. (1) · Humanigen, Inc. (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Institut Paoli-Calmettes (1) · Leland Metheny (1) · Oshadi Drug Administration (1) · Renato Melaragno (1) · Samsung Medical Center (1) · Shanghai Jiao Tong University School of Medicine (1) · Shanghai Zhangjiang Biotechnology Limited Company (1) · SymBio Pharmaceuticals (1)
United States (6) · China (4) · France (2) · Israel (2) · Australia (1) · Czechia (1) · Germany (1) · Italy (1) · Japan (1) · Poland (1) · Senegal (1) · Singapore (1) · South Korea (1) · Spain (1)
Abhay Singh, MD, MPH (1) · Jiong HU, M.D., (1) · Jun Zhu, M.D. (1) · Leland Metheny, MD (1) · Morgan Lam (1) · Moshe Gatt, MD (1) · Renato J Aguilera, PhD (1) · Ryan D. Cassaday, MD (1) · Won Seog Kim, MD (1)